Canon Medical Systems
This article was originally published in The Gray Sheet
Executive Summary
Firm switches to per-study-fee marketing strategy for its CXDI-22 digital radiography system that will allow smaller medical institutions to use the technology without up-front capital investments for leasing or purchasing the equipment. The CXDI-22 lists for about $200,000. Under new application service provider (ASP) model, users pay for what they use per month, as well as a minimum charge over a contracted time, the firm says in Nov. 27 release. At the Nov. 26-Dec. 1 Radiological Society of North America conference, Canon showcased the DR system in conjunction with Stentor's medical image and information system, iSite, for delivering diagnostic quality images over existing hospital networks. "By offering our customers a choice in the way they obtain their systems, we expect to penetrate the digital image market and allow more customers to experience the benefit of digital technology," Eric Kuramato, director and general manager, Canon Medical Systems explained
You may also be interested in...
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.